Post-translational mAbs

Generating mAbs that target post-translational modifications such as phosphorylations could open up a host of new targets for cancer and other diseases associated with aberrant protein modifications, but the low immunogenicity of the modified sites has thus far stymied the use of conventional mAb-generation platforms.

University of California, San Francisco researchers have now developed a structure-guided phage display platform capable of producing mAbs that target post-translational modifications.¹ Next, the team will have to show that the mAbs target endogenous proteins in vivo...